|Bid||36.10 x 1000|
|Ask||41.50 x 800|
|Day's Range||38.72 - 40.51|
|52 Week Range||27.85 - 54.45|
|Beta (3Y Monthly)||3.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 2, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.33|
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover, M.D., plans to step down as the Company’s President and Chief Executive Officer. Dr. Ciechanover will remain in his role as President and CEO until the earlier of the appointment of his successor or June 30, 2019. “Isaac is a visionary founder and CEO who started Atara in honor of his mother to transform the lives of patients with serious medical conditions,” said Carol G. Gallagher, Pharm.
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors Atara’s next-generation CAR T.
Second EBV‑associated solid tumor with encouraging responses to tab-cel®Tab-cel® safety appears consistent with a favorable risk profile and previous observationsResults were.
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
On Wednesday, July 11, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ArQule Inc. (NASDAQ: ARQL), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Atara Biotherapeutics Inc. (NASDAQ: ATRA).